Hims & Hers Health (HIMS) Competitors $65.52 +5.25 (+8.71%) Closing price 07/30/2025 03:59 PM EasternExtended Trading$66.06 +0.54 (+0.82%) As of 07/30/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HIMS vs. NTRA, FMS, GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, and PRVAShould you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Fresenius Medical Care AG & Co. KGaA (FMS), Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry. Hims & Hers Health vs. Its Competitors Natera Fresenius Medical Care AG & Co. KGaA Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Do insiders and institutionals believe in HIMS or NTRA? 63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 13.7% of Hims & Hers Health shares are held by insiders. Comparatively, 7.6% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate HIMS or NTRA? Hims & Hers Health currently has a consensus target price of $39.83, indicating a potential downside of 39.20%. Natera has a consensus target price of $183.76, indicating a potential upside of 30.37%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92Natera 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06 Which has more risk & volatility, HIMS or NTRA? Hims & Hers Health has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Does the media refer more to HIMS or NTRA? In the previous week, Hims & Hers Health had 43 more articles in the media than Natera. MarketBeat recorded 81 mentions for Hims & Hers Health and 38 mentions for Natera. Natera's average media sentiment score of 1.15 beat Hims & Hers Health's score of 0.37 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 20 Very Positive mention(s) 4 Positive mention(s) 50 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Natera 21 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, HIMS or NTRA? Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.48B9.93$126.04M$0.6994.96Natera$1.70B11.34-$190.43M-$1.47-95.89 Is HIMS or NTRA more profitable? Hims & Hers Health has a net margin of 9.24% compared to Natera's net margin of -10.36%. Hims & Hers Health's return on equity of 22.75% beat Natera's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health9.24% 22.75% 15.51% Natera -10.36%-18.29%-11.68% SummaryHims & Hers Health beats Natera on 9 of the 17 factors compared between the two stocks. Get Hims & Hers Health News Delivered to You Automatically Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIMS vs. The Competition Export to ExcelMetricHims & Hers HealthMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$13.49B$2.08B$5.63B$20.97BDividend YieldN/AN/A4.71%3.61%P/E Ratio94.9637.9530.2028.76Price / Sales9.9310.56455.8756.51Price / Cash171.1455.7536.0123.15Price / Book30.339.138.344.51Net Income$126.04M-$63.64M$3.25B$993.26M7 Day Performance14.38%-4.26%-2.15%-1.79%1 Month Performance31.20%6.79%7.97%2.02%1 Year Performance208.47%5.43%36.49%7.31% Hims & Hers Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIMSHims & Hers Health2.1945 of 5 stars$65.52+8.7%$39.83-39.2%+209.1%$13.49B$1.48B94.961,637Trending NewsUpcoming EarningsAnalyst DowngradeInsider TradeNTRANatera2.7885 of 5 stars$140.61+1.2%$183.76+30.7%+44.2%$19.23B$1.70B-95.804,434Positive NewsAnalyst UpgradeInsider TradeFMSFresenius Medical Care AG & Co. KGaA3.3529 of 5 stars$25.86-2.2%$27.80+7.5%+31.4%$15.18B$19.49B23.091,384GHGuardant Health3.9771 of 5 stars$44.43+0.0%$54.45+22.6%+24.5%$5.51B$739.02M-13.112,021Trending NewsOPCHOption Care Health4.6205 of 5 stars$29.78+0.3%$35.50+19.2%-2.3%$4.88B$5.00B24.038,088News CoveragePositive NewsGap DownRDNTRadNet3.6944 of 5 stars$57.72+0.5%$69.60+20.6%-5.0%$4.34B$1.83B-134.3611,021Positive NewsBTSGBrightSpring Health Services1.8427 of 5 stars$20.45-0.4%$24.90+21.8%+68.3%$3.59B$11.27B73.0235,000Upcoming EarningsGap UpSHCSotera Health2.9984 of 5 stars$12.33+0.2%$16.00+29.8%-12.4%$3.50B$1.10B154.213,000Upcoming EarningsSGRYSurgery Partners2.756 of 5 stars$22.27+4.7%$33.33+49.7%-28.4%$2.85B$3.17B-14.5515,000Upcoming EarningsAnalyst ForecastCONConcentra Group Holdings Parent3.121 of 5 stars$19.93+1.3%$28.50+43.0%-12.0%$2.55B$1.93B14.8711,250Upcoming EarningsPRVAPrivia Health Group3.8511 of 5 stars$19.74+0.1%$28.38+43.8%-6.8%$2.41B$1.74B164.441,140Positive NewsUpcoming Earnings Related Companies and Tools Related Companies NTRA Competitors FMS Competitors GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors CON Competitors PRVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HIMS) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.